Mosaiques Diagnostics is pleased to announce that the collaborative research project CephaMed has been awarded funding by the German BMFTR

CephaMed ("Development of Cephaeline as a molecular-based therapy with predictive biomarkers in precision medicine for bladder cancer") aims to develop a novel molecular-based therapeutic approach for bladder cancer while identifying predictive biomarkers to support patient stratification and treatment decisions.

The project will run from 2026 to 2028 and focuses on:

• Development of Cephaeline as a potential therapeutic approach for bladder cancer.
• Identification of predictive biomarkers to support precision medicine.
• Advancing personalized treatment strategies for patients with bladder cancer.